372 related articles for article (PubMed ID: 906404)
81. Effect of BCG immunotherapy on alloantigen-induced blastogenesis and cytotoxicity of lymph node lymphocytes in patients with melanoma.
Callery CD; Morton DL; Golub SH
Surg Forum; 1979; 30():152-4. PubMed ID: 161421
[No Abstract] [Full Text] [Related]
82. Immunological effects of BCG in malignant melanoma: two modes of administration compared.
Bluming AZ; Vogel CL; Ziegler JL; Mody N; Kamya G
Ann Intern Med; 1972 Mar; 76(3):405-11. PubMed ID: 5015915
[No Abstract] [Full Text] [Related]
83. Immunotherapy for melanoma.
Vaisrub S
JAMA; 1973 Sep; 225(10):1242. PubMed ID: 4542440
[No Abstract] [Full Text] [Related]
84. Effect of BCG (Tice strain) on primary sensitization to 2,4-dinitrochlorobenzene and on established delayed hypersensitivity in human malignant melanoma.
Mavligit GM; Gutterman JU; Hersh EM
J Natl Cancer Inst; 1976 Oct; 57(4):749-51. PubMed ID: 1003526
[TBL] [Abstract][Full Text] [Related]
85. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
[TBL] [Abstract][Full Text] [Related]
86. [Immunotherapy of melanoma].
Dréno B
Bull Acad Natl Med; 2010 Oct; 194(7):1373-81. PubMed ID: 22043632
[TBL] [Abstract][Full Text] [Related]
87. Immunology of human malignant melanoma.
Lewis MG
Ser Haematol; 1972; 5(5):44-65. PubMed ID: 4598040
[No Abstract] [Full Text] [Related]
88. Non-specific and specific immunotherapy in patients with melanoma.
Seigler HF; Shingleton WW; Metzgar RS; Buckley CE; Bergoc PM; Miller DS; Fetter BF; Phaup MB
Surgery; 1972 Jul; 72(1):162-74. PubMed ID: 4555924
[No Abstract] [Full Text] [Related]
89. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
[TBL] [Abstract][Full Text] [Related]
90. Monitoring of immunologic status of patients receiving BCG therapy for malignant disease.
Gross NJ; Eddie-Quartey AC
Cancer; 1976 May; 37(5):2183-93. PubMed ID: 769946
[TBL] [Abstract][Full Text] [Related]
91. Influence of preexisting tumor immunity on Bacillus Calmette-Guérin immunotherapy of guinea pigs with both regional and disseminated tumor.
Jessup JM; Riggs CW; Hanna MG
Cancer Res; 1977 Aug; 37(8 Pt 1):2565-73. PubMed ID: 872084
[No Abstract] [Full Text] [Related]
92. Immunotherapy of malignancy in humans. Current status.
Holmes EC; Eilber FR; Morton DL
JAMA; 1975 Jun; 232(10):1052-5. PubMed ID: 236402
[TBL] [Abstract][Full Text] [Related]
93. Potentiation and arming of lymphocyte mediated immunity by sera from melanoma patients.
Vanwijck R; Bouillenne C; Malek-Mansour S
Eur J Cancer (1965); 1975 Apr; 11(4):267-76. PubMed ID: 1079770
[No Abstract] [Full Text] [Related]
94. Comparative evaluation of lymphocyte subpopulations, delayed cutaneous hypersensitivity reactions and autoantibody formation in cancer patients.
Pichler WJ; Stingl G; Wagner G; Micksche M; Neumann H; Knapp W
Osterr Z Onkol; 1977 Nov; 4(5-6):110-7. PubMed ID: 202907
[No Abstract] [Full Text] [Related]
95. [Immunotherapy of carcinoma of the lung].
Sega E; Mineo TC; Rea SR; Sega FM; Ricci C
Recenti Prog Med; 1978 Mar; 64(3):293-309. PubMed ID: 351751
[No Abstract] [Full Text] [Related]
96. Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.
Seigler HF; Shingleton WW; Pickrell KL
Plast Reconstr Surg; 1975 Mar; 55(3):294-8. PubMed ID: 1118487
[TBL] [Abstract][Full Text] [Related]
97. Re-inventing intratumoral immunotherapy for melanoma.
Triozzi PL; Tuthill RJ; Borden E
Immunotherapy; 2011 May; 3(5):653-71. PubMed ID: 21554094
[TBL] [Abstract][Full Text] [Related]
98. [Immunotherapeutic possibilities for treatment of malignant melanomas].
Kokoschka EM
Hautarzt; 1979 Dec; 30(12):656-61. PubMed ID: 317654
[TBL] [Abstract][Full Text] [Related]
99. [Current aspects of melanoma research. II. Immunotherapy].
Wätzig V
Dermatol Monatsschr; 1977 May; 163(5):359-66. PubMed ID: 881082
[No Abstract] [Full Text] [Related]
100. [Effect of intra-lesional injection of tuberculin-active protein on metastatic nodules of human malignant melanoma].
Saida T
Nihon Hifuka Gakkai Zasshi; 1982 Nov; 92(13):1399-414. PubMed ID: 6984865
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
